These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 15774819)

  • 1. NF-kappaB and the innate immune response in the respiratory distress syndrome of the newborn: commentary on the article by Cheah et al. on page 616.
    Chatila TA; Smith JB
    Pediatr Res; 2005 May; 57(5 Pt 1):613-5. PubMed ID: 15774819
    [No Abstract]   [Full Text] [Related]  

  • 2. Surfactant treatment of neonatal acute respiratory distress syndrome: is "fortification" the answer?
    Chima RS; Zingarelli B
    Crit Care Med; 2007 Oct; 35(10):2442-3. PubMed ID: 17885382
    [No Abstract]   [Full Text] [Related]  

  • 3. [On the treatment of the respiratory distress syndrome in premature infants with tris(hydroxymethyl)-aminomethane (THAM) and wetting agents].
    Jarre W; Ketterle W; Reinwein H
    Helv Paediatr Acta; 1965 Apr; 20(1):27-39. PubMed ID: 5828973
    [No Abstract]   [Full Text] [Related]  

  • 4. Dexamethasone suppresses expression of Nuclear Factor-kappaB in the cells of tracheobronchial lavage fluid in premature neonates with respiratory distress.
    Aghai ZH; Kumar S; Farhath S; Kumar MA; Saslow J; Nakhla T; Eydelman R; Strande L; Stahl G; Hewitt C; Nesin M; Rahman I
    Pediatr Res; 2006 Jun; 59(6):811-5. PubMed ID: 16641216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NF-kappaB and the immune response.
    Hayden MS; West AP; Ghosh S
    Oncogene; 2006 Oct; 25(51):6758-80. PubMed ID: 17072327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Exogenous surfactant preparations].
    Helewski K; Kowalczyk-Ziomek G; Konecki J
    Pneumonol Alergol Pol; 1998; 66(1-2):127-32. PubMed ID: 9658893
    [No Abstract]   [Full Text] [Related]  

  • 7. Nuclear factor-kappaB- and glucocorticoid receptor alpha- mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome. Evidence for inflammation-induced target tissue resistance to glucocorticoids.
    Meduri GU; Muthiah MP; Carratu P; Eltorky M; Chrousos GP
    Neuroimmunomodulation; 2005; 12(6):321-38. PubMed ID: 16557033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the mechanisms of infant respiratory distress and chronic lung disease.
    Copland IB; Post M
    Am J Respir Cell Mol Biol; 2002 Mar; 26(3):261-5. PubMed ID: 11867331
    [No Abstract]   [Full Text] [Related]  

  • 9. Surfactant for respiratory distress syndrome.
    Bierman SF
    N Engl J Med; 1989 Sep; 321(12):834. PubMed ID: 2671737
    [No Abstract]   [Full Text] [Related]  

  • 10. Synthetic surfactants in infants with respiratory distress syndrome.
    Perlman JM; Moya F
    N Engl J Med; 1992 Jun; 326(25):1703-4; author reply 1704-5. PubMed ID: 1588992
    [No Abstract]   [Full Text] [Related]  

  • 11. Nuclear factor-kappaB motif and interferon-alpha-stimulated response element co-operate in the activation of guanylate-binding protein-1 expression by inflammatory cytokines in endothelial cells.
    Naschberger E; Werner T; Vicente AB; Guenzi E; Töpolt K; Leubert R; Lubeseder-Martellato C; Nelson PJ; Stürzl M
    Biochem J; 2004 Apr; 379(Pt 2):409-20. PubMed ID: 14741045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Artificial surfactant to prevent and treat neonatal respiratory distress syndrome.
    Enhorning G
    Pediatrics; 1980 Nov; 66(5):799-800. PubMed ID: 7432889
    [No Abstract]   [Full Text] [Related]  

  • 13. Involvement of nuclear factor-kB and Nurr-1 in cytokine-induced transcription of proopiomelanocortin gene in AtT20 corticotroph cells.
    Takayasu S; Iwasaki Y; Nigawara T; Asai M; Yoshida M; Kageyama K; Suda T
    Neuroimmunomodulation; 2010; 17(2):88-96. PubMed ID: 19923853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Factors affecting clinical response to surfactant therapy in neonates with severe respiratory distress syndrome].
    Fujiwara T; Chida S; Konishi M
    Nihon Kyobu Shikkan Gakkai Zasshi; 1991 Jan; 29(1):29-34. PubMed ID: 2041254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical symptoms and biochemical changes in the respiratory distress syndrome].
    Mentzel H
    Dtsch Med J; 1970 Mar; 21(5):261-3. PubMed ID: 5436894
    [No Abstract]   [Full Text] [Related]  

  • 16. Circuitry of nuclear factor kappaB signaling.
    Hoffmann A; Baltimore D
    Immunol Rev; 2006 Apr; 210():171-86. PubMed ID: 16623771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of nuclear factor-kappaB in the immune system and bone.
    Jimi E; Ghosh S
    Immunol Rev; 2005 Dec; 208():80-7. PubMed ID: 16313342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of idiopathic respiratory distress syndrome--prospective method by artificial surfactant (author's transl)].
    Kobayashi T; Sada T; Murakami S
    Masui; 1979 Oct; 28(10):1012-7. PubMed ID: 513270
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pulmonary surfactant and the immune system].
    Griese M
    Monatsschr Kinderheilkd; 1992 Jan; 140(1):57-61. PubMed ID: 1565109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms to explain surfactant responses.
    Jobe AH
    Biol Neonate; 2006; 89(4):298-302. PubMed ID: 16770069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.